Status:
UNKNOWN
TelePharmaceutical Care Diabetes Trial
Lead Sponsor:
Rio Grande do Sul State Health Department - SES/RS
Collaborating Sponsors:
Agnes Nogueira Gossenheimer
Ana Paula Rigo
Conditions:
Diabete Mellitus
Diabete Type 2
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The prevalence of Diabetes Mellitus (DM) in the world is currently around 9.3% of adults aged between 20 and 79 years, which corresponds to 463 million people living with DM, and about 80% of these pe...
Eligibility Criteria
Inclusion
- People aged 18 years or older, with a previous diagnosis of type 2 diabetes mellitus and who take dapagliflozin at the Special Medicines Pharmacy of the State of Rio Grande do Sul, Brazil, will be selected. In addition, it will be considered an inclusion criterion that the person is available to receive phone calls.
Exclusion
- Do not present a telephone record registered in the system;
- Be participating in another diabetes education program;
- Pregnancy;
- Severe cognitive problems;
- Communication difficulties;
- Presence of other injuries;
- Patients who are hospitalized at the time of recruitment will also be excluded from participation in this study.
Key Trial Info
Start Date :
June 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2023
Estimated Enrollment :
124 Patients enrolled
Trial Details
Trial ID
NCT05380596
Start Date
June 1 2022
End Date
January 1 2023
Last Update
May 19 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rio Grande do Sul State Health Department - SES/RS
Porto Alegre, Rio Grande do Sul, Brazil, 90110-150